Novo Nordisk’s Distribution Push Collides With Margin Squeeze as Pipeline Nears Inflection
Published on 05/17/2026 at 16:17 | Redaktion boerse-global.de
Novo Nordisk is walking a tightrope between booming digital access and brutal pricing pressure. The Danish drugmaker has landed its oral Ozempic tablet on Amazon Pharmacy, a move that promises same-day delivery to nearly 3,000 US cities by mid-2026 and a target of 4,500 by year-end. The logistics push complements existing tie-ups with Weight Watchers and GoodRx, giving the company a direct-to-patient channel that bypasses traditional pharmacy bottlenecks.
Yet the stock has not rewarded the strategy. Shares closed at €38.56 on Friday, down 1.82% on the day, and have fallen 13.70% since the start of the year. Over twelve months, the decline has reached 34.93%. The disconnect between operational wins and market sentiment masks a more nuanced story.
Oral Wegovy Surpasses Forecasts While US Pricing Bites
The oral version of Wegovy has become a bright spot. Since its launch, more than 2 million prescriptions have been written in the US; in the first full week alone, weekly scripts topped 18,000. The tablet now commands 65% of all new oral GLP-1 prescriptions in the country. First-quarter revenue from Wegovy’s oral formulation reached 2.26 billion Danish kroner, comfortably beating the Jefferies consensus estimate.
But the US business as a whole shrank 11% in the first quarter, adjusted for currency. The culprit is falling net selling prices, which volume growth has only partly offset. Novo Nordisk is betting that the Amazon channel will accelerate patient access and lift volumes further, but margin pressure in its largest market remains a stubborn drag.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
India Generics Provide a Preview of the Post-Patent Era
Nowhere is the pricing threat more visible than India. After Novo’s key GLP-1 patent expired in March 2026, more than a dozen local manufacturers — including Sun Pharma, Dr. Reddy’s, Cipla, and Zydus Lifesciences — launched their own semaglutide copies. The Danish company responded by slashing list prices: Ozempic fell 38%, Wegovy 48%.
The lower prices have worked in volume terms. Sales of Novo’s diabetes and obesity medicines in India jumped 40% in April. But the arithmetic is unforgiving: higher unit sales at sharply lower prices squeeze margins. Investors view India as a harbinger for other emerging markets where exclusivity will soon erode.
Pipeline Advances: CagriSema and Beyond
Away from the pricing battlefield, the pipeline offers a counter-narrative. CagriSema, the next-generation obesity candidate, was submitted to the FDA in December 2025, with a decision expected by the end of 2026. In a pivotal Phase 3 trial, patients achieved an average 22.7% weight loss after 68 weeks, compared with 2.3% in the placebo group. A high-dose Phase 3 study is planned for the second half of this year.
Novo Nordisk is also preparing a filing for Etavopivat, a treatment for sickle cell disease. The drug reduced painful vaso-occlusive crises by 27% in a late-stage study, significantly outperforming the control arm. The company targets a regulatory submission in the second half of 2026.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Management has reiterated an upbeat tone despite the headwinds. The full-year guidance for revenue and operating profit has been lifted, though 2026 is still expected to see declining sales and operating profit at constant exchange rates.
Catalysts on the Calendar
The next major events for shareholders come in quick succession. On June 7, Novo Nordisk will present at the American Diabetes Association conference, where analysts expect detailed updates on the research strategy. Two months later, on August 5, the half-year results will offer a hard look at how the Amazon rollout, Indian price cuts, and pipeline progress are shaping financial performance. Until then, the market remains focused on three variables: distribution reach, generic erosion, and the FDA’s timeline for CagriSema.
Ad
Novo Nordisk Stock: New Analysis - 17 May
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
